Cerulean (CERU) Shares Up 4% On Phase 1b/2 CRLX101 Trial Results

Shares of Cerulean Pharma Inc. (CERU) are higher by more than 4% to $11.12 in after-hours trading on Thursday, after the company announced phase 1b/2 trial of CRLX101 in combination with Avastin in relapsed renal cell carcinoma met primary endpoint. “The top-line results from this trial in a difficult-to-treat patient population are encouraging,” said in […] View the full post at: Cerulean (CERU) Shares Up 4% On Phase 1b/2 CRLX101 Trial Results Related posts: Atlas Pipeline (APL) Shares Soar On Nat Gas Asset Sale Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock